能動植込み型医療機器の世界市場-2023年～2030年

概要

能動植込み型医療機器とは、診断または治療目的で人体に全体的または部分的に導入することを意図した能動的な医療機器です。能動植込み型医療機器には、ペースメーカー、除細動器、輸液ポンプ、補助人工心臓、人工内耳、神経刺激装置など、さまざまな機器が含まれます。

能動植込み型医療機器は、長期間にわたって身体に直接接触するように設計されており、患者の健康と安全を守るために厳しい基準や要件が課されています。また、能動植込み型医療機器は、心臓血管、神経学、整形外科など、さまざまな用途で広く使用されています。

市場力学

機器発売の増加

能動植込み型医療機器の製品発売が増加していることは、市場成長の重要な促進要因となっています。また、多くの主要企業が新しい治療装置を発売することで、市場の進歩に大きな役割を果たしています。

例えば、2023年5月、MicroPort CRM社は、植込み型ペースメーカーの最新シリーズであるAlizeaTMとCeleaTMの米国FDA承認を取得しました。これらは最新のペースメーカー技術で、小型で皮下に目立たないため、植え込みが容易です。

また、メドトロニックは2022年12月、パーキンソン病などの神経疾患患者に電気的な脳深部刺激（DBS）治療を提供するブレインセンスと呼ばれる技術を搭載した脳深部植込み型刺激装置パーセプトPCを発売しました。

さらに、2022年8月、メドトロニックplc.は、胸骨の下にリードを入れる血管外植込み型除細動器（EV ICD）システム除細動器を発売しました。

さらに、慢性疾患の有病率や発症率の上昇、能動的植え込み型医療機器の使用による低侵襲手術の採用拡大などの重要な成長促進要因が、予測期間中の市場を牽引すると予想されます。

植込み型ペースメーカーに関連する合併症

植え込み型ペースメーカーに関連する合併症は、予測期間における市場の成長を妨げると思われます。Mayo Clinicによると、特に患者が血液希釈剤を服用している場合、ペースメーカーの部位に腫れ、出血、あざが生じる可能性があります。また、ペースメーカー部位付近の血栓塞栓症（血の塊）やペースメーカー付近の血管や神経の損傷を引き起こす可能性もあります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • デバイス上市の増加
    • 成長
  • 抑制要因
    • 植込み型ペースメーカーに関する合併症
    • はい
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• DMI意見

第6章 COVID-19分析

第7章 デバイスタイプ別

• 植込み型除細動器
  • 経静脈的植込み型除細動器
    • 両心室植込み型除細動器
    • 両チャンバー型植込み型除細動器
    • シングルチャンバー植込み型除細動器
  • 皮下植込み型除細動器
• 植込み型心臓ペースメーカー
• 補助人工心臓
• 神経刺激装置
• 植込み型補聴器
• 植込み型心臓モニター
• 植込み型グルコースモニター

第8章 用途別

• 心臓血管
• 神経
• 整形外科
• その他

第9章 エンドユーザー別

• 病院
• 外来手術センター
• 心臓センター
• 神経センター
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• Boston Scientific Corporation
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Medtronic Plc
• MED-EL
• Nurotron Biotechnology Co. Ltd.
• Abbott Laboratories
• Cochlear Ltd
• Sanova Holding AG
• LivaNova Plc
• Biotronik Inc.
• Osypka Medical

第13章 付録

Overview

An active implantable medical device is an active medical device intended to be totally or partially introduced into the human body for diagnostic or therapeutic purposes. An active implantable medical device includes a wide range of devices, including pacemakers, defibrillators, infusion pumps, ventricular assist systems and devices, cochlear implants, and neurostimulators.

Active implantable medical devices are designed to remain in direct contact with the body for extended periods and they are subject to rigorous standards and requirements to protect the health and safety of patients. Active implantable medical devices are also widely used in various applications such as in the cardiovascular, neurology, and orthopedic.

Market Dynamics

Increasing device launches

The increasing number of product launches for active implantable medical devices acts as a significant driver for market growth. Also, many key players play a major role in the advancements of the market by launching new treatment devices.

For instance, in May 2023, MicroPort CRM received U.S. FDA approval for its latest range of implantable pacemakers, AlizeaTM and CeleaTM. These are modern pacemaker technology that is small and discrete under the skin, making it easier to implant.

Also, in December 2022, Medtronic launched a deep brain implantable stimulator called Percept PC which is equipped with technology called BrainSense to provide electrical deep brain stimulation (DBS) treatment to patients with neurological diseases such as Parkinson's disease.

Additionally, in August 2022, Medtronic plc. Launched an extravascular implantable cardioverter defibrillator (EV ICD) system defibrillator with a lead put under the breastbone.

Furthermore, significant growth drivers such as the rising prevalence and incidence of chronic diseases, and the growing adoption of minimally invasive surgeries by using active implantable medical devices are expected to drive the market in the forecast period.

Complications related to implantable pacemakers

The complications related to implanted pacemakers will hamper the market growth in the forecast period. As per the Mayo Clinic, swelling, bleeding, or bruising can occur at the pacemaker site, particularly if the patient is taking blood thinners. It can also cause thromboembolism (blood clots) near the pacemaker site or the blood vessel or nerve damage near the pacemaker.

Segment Analysis

The global active implantable medical devices market is segmented based on device type, application, end users, and region.

Neurostimulators accounted for approximately 47.3% of the market share

An implantable neurostimulator delivers mild electrical signals to the epidural space near the spine through thin wires called leads. Neurostimulators are expected to hold the largest market share over the period forecast owing to increasing new neurostimulator launches and technical advancements.

For instance, in April 2023, Synapse Biomedical, Inc. launched the NeuRx Diaphragm Pacing System which is a battery-powered device that delivers electrical stimulation via four percutaneous intramuscular electrodes implanted into the diaphragm with minimally invasive laparoscopy.

Additionally, in December 2022, Abbott launched the Eterna spinal cord stimulation (SCS) system which is the smallest implantable, rechargeable spinal cord stimulator for the treatment of chronic pain.

Geographical Analysis

North America is expected to hold a significant position in the global active implantable medical devices market share

The global active implantable medical devices market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as the rising prevalence of atrial fibrillation, and increasing adoption of cardiac pacemaker implantation, this trend is anticipated to continue throughout the forecast period.

For instance, according to the National Institute of Health 2022, it is estimated that in the United States, the number of people with an implantable pacemaker is between 500,000 and 3 million. The chance of pacemaker implantation increases with age for over 70% of all pacemakers that are implanted in patients over the age of 65.

Additionally, according to Healthline Media, it is estimated that the prevalence of atrial fibrillation in the United States ranges from about 2.7 million to 6.1 million. It is estimated to rise to 12.1 million in 2030. Hence, due to the increasing number of people with atrial fibrillation, the rate of pacemaker implantation is expected to increase to treat heart diseases.

COVID-19 Impact Analysis:

The COVID-19 pandemic has had a significant impact on the global active implantable medical devices market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatments, device launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the active implantable medical devices market is expected to be moderately affected over the forecast period.

Competitive Landscape

The major global players in the market include: Boston Scientific Corporation, Medtronic Plc, MED-EL, Nurotron Biotechnology Co. Ltd., Abbott Laboratories, Cochlear Ltd, Sanova Holding AG, LivaNova Plc, Biotronik Inc., Osypka Medical among others.

Key Developments

• In June 2023, Medics invested £1.8 million for clinical trials with the aim of precisely targeting heart patients who need tiny defibrillators to be fitted under their skin with the aim of reducing deaths from sudden cardiac arrests.
• In June 2021, India Medtronic Private Limited launched Micra AV, a little, a fully self-contained pacemaker that uses a minimally invasive method to provide sophisticated pacing technology to those with atrioventricular (AV) block.

Why Purchase the Report?

• To visualize the global active implantable medical devices market segmentation based on device type, application, end users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of active implantable medical devices market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global active implantable medical devices market report would provide approximately 61 tables, 62 figures, and 185 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Device Type
• 3.2. Snippet by Application
• 3.3. Snippet by End Users
• 3.4. Snippet by Region

4. Market Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing device launches
    • 4.1.1.2.
  • 4.1.2. Restraints
    • 4.1.2.1. Complications related to implantable pacemakers
    • 4.1.2.2.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Device Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 7.1.2. Market Attractiveness Index, By Device Type
• 7.2. Implantable Cardioverter Defibrillators*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Transvenous Implantable Cardioverter Defibrillators
    • 7.2.3.1. Biventricular Implantable Cardioverter Defibrillators
    • 7.2.3.2. Dual-Chamber Implantable Cardioverter Defibrillators
    • 7.2.3.3. Single-Chamber Implantable Cardioverter Defibrillators
  • 7.2.4. Subcutaneous Implantable Cardioverter Defibrillators
• 7.3. Implantable Cardiac Pacemakers
• 7.4. Ventricular Assist Devices
• 7.5. Neurostimulators
• 7.6. Implantable Hearing Devices
• 7.7. Implantable Heart Monitors
• 7.8. Implantable Glucose Monitors

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Cardiovascular*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Neurology
• 8.4. Orthopedic
• 8.5. Others

9. By End Users

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 9.1.2. Market Attractiveness Index, By End Users
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Ambulatory Surgical Centers
• 9.4. Cardiac Centers
• 9.5. Neuro Centers
• 9.6. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Boston Scientific Corporation
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Medtronic Plc
• 12.3. MED-EL
• 12.4. Nurotron Biotechnology Co. Ltd.
• 12.5. Abbott Laboratories
• 12.6. Cochlear Ltd
• 12.7. Sanova Holding AG
• 12.8. LivaNova Plc
• 12.9. Biotronik Inc.
• 12.10. Osypka Medical

LIST NOT EXHAUSTIVE.

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us